期刊文献+

ER、PR、P53在子宫内膜癌中的表达及对预后的影响 被引量:14

Expressions of estrogen receptor,progestin receptor and P53 in endometrial carcinoma and their effect on its prognosis
下载PDF
导出
摘要 目的评估ER、PR、P53在子宫内膜癌(endometrial cancer,EC)中的表达及对预后的影响。方法分析我院2005年1月-2011年3月173例子宫内膜癌患者的ER(estrogen receptor)、PR(progestin receptor)、P53(P53 protein)与子宫内膜癌的病理及预后关系。结果 ER在子宫内膜癌的不同类型、病理要素间表达有统计学差异,ER阳性的生存率(100%),显著高于ER阴性生存率(88.3%)(P<0.05),ER表达>75%生存率(100%)与<75%生存率(95.3%)无统计学差异(P>0.05)。PR在子宫内膜癌的不同类型、病理要素间表达有统计学差异,PR阳性与阴性的生存率、>75%与<75%的生存率有统计学差异(P<0.05)。P53在两型子宫内膜癌中表达有统计学差异,在病理要素间表达无统计学差异,阳性与阴性的生存率无统计学差异(P>0.05),表达>75%与<75%生存率有统计学差异(P<0.05)。结论 ER、PR和P53与子宫内膜癌类型、病理要素相关,是影响预后、判断良恶性的指标。 Objective To assess the expressions of estrogen receptor (ER), progestin receptor (PR), and P53 in endometrial cancer and their effect on its prognosis. Methods Correlation of expressions of ER, PR and P53 in 173 endometrial cancer patients admitted to our hospital from January 2005 to March 2011 with the pathology and prognosis of endometrial cancer was analyzed. Results No significant difference was observed in expression of ER in different types and pathology of endometrial cancer. The survival rate of ER-positive patients was significantly higher than that of ER-negative patients (100% vs 88.3%, P〈0.05). No significant difference was found in ER-positive patients with a survival rate 〉75% or 〈75% (100% vs 95.3%, P〉0.05). The expression of PR was significantly different in different types and pathology of endometrial cancer. The survival rate of PR-positive and negative patients with a survival rate 〉75% or 〈75% was significantly different (P〈0.05). The expression of P53 was significantly different in different types of endometrial cancer(P〈0.05) with no significant difference in pathology of endometrial carcinoma and in survival rate of P53-positive or negative patients. The survival rate of PR positive or negative patients with a survival rate 〉75% or 〈75% was significantly different (P〈0.05). Conclusion ER, PR and P53 are correlated with the types of endometrial cancer and can thus be used as indications for its prognosis and for the judgment of whether it is malignant or benign.
机构地区 解放军总医院
出处 《军医进修学院学报》 CAS 2012年第1期27-29,41,共4页 Academic Journal of Pla Postgraduate Medical School
基金 国家自然科学基金项目(30872749)~~
关键词 子宫内膜癌 雌激素受体 孕激素受体 P53 免疫组化 endometrial cancer estrogen receptor progestin receptor P53 immunohistochemistry
  • 相关文献

参考文献10

  • 1Meenakshi S, Zaino RJ, Filiaci V J, et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma : a gynecologic oncology group study [ J ] . Gynecol Oncol, 2007, 106 ( 2 ) : 325-333.
  • 2Hoskins WJ, Perez CA, Young RC, et al. Principles and practice of gynecologic oncology [ M ] . Philadelphia : Lippincott Williams and Wilkins, 2000 : 1005-1007.
  • 3Kounelis S, Kapranos N, Kouri E, et al. Immunohistochemical profile of endometrial adenocarcinoma : a study of 61 cases/md review of the literature [ J ] . Mod Pathol, 2000, 13 ( 4 ) : 379-388.
  • 4Gielen SC, Hanekamp EE, Hanifi-moghaddam P, et al. Growth regulation and transcriptional activities of estrogen and progesterone in human endometrial cancer cells [ J ] . Int J Gynecol Cancer, 2006, 16 ( 1 ) : 110-120.
  • 5Ishikawa A, Kudo M, Nakazawa N, et al. Expression of keratinocyte growth factor and its receptor in human endometrial cancer in cooperation with steroid hormones [ J ] . Int J Oncol, 2008.32 ( 3 ) : 565-574.
  • 6Vandenput I, Trovik J, Leunen K, et al. Evolution in endometrial cancer : evidence from an immunohistochemical study [ J ] . Int J Gynecol Cancer, 2011, 21 ( 2 ) : 316-322.
  • 7Neubauer NL, Ward EC, Patel P, et al. Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59- mediated apoptosis [ J ] . Horm Cancer, 2011, 2 ( 3 ) : 170-181.
  • 8Deb SP. Cell cycle regulatory functions of the human oncoprotein MDM2 [ J ]. Mol Cancer Res, 2003, 1 (14): 1009-1016.
  • 9Ferrandina G, Oreste FR, Valerio G, et al. Expression of cyclooxygenase-2 ( cox-2 ), receptors for estrogen ( ER ), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer [ J ] . Gynecol Oncol, 2005, 98 ( 3 ) : 383-389.
  • 10Vandenput I, Capoen A, Coenegrachts L, et al. Expression of ERCC1, p53, and Class III 13-Tubulin Do Not Reveal Chemoresistance in Endometrial Cancer : Results From an 1071-1077 Study[ J ]. Int J Gynecol Cancer, 2011,21( 6 ).

同被引文献188

引证文献14

二级引证文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部